Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for 68062P106 since 12/18/2024, newest first.
| Filer | % of Class | Filed | |
|---|---|---|---|
|
FMR LLC
13G/A
Amendment 2
|
13.8% |
8/6/2026
Event 6/30/2026
|
|
| FMR LLC | 13.8% | ||
| Abigail P. Johnson | 13.8% | ||
| BlackRock, Inc. 13G/A Amendment 1 | 7.1% |
7/29/2026
Event 6/30/2026
|
|
| Janus Henderson Group PLC 13G/A Amendment 2 | 8.2% |
5/15/2026
Event 3/31/2026
|
|
| Bain Capital Life Sciences Opportunities IV, L.P. 13G/A Amendment 4 | 8.2% |
5/15/2026
Event 3/31/2026
|
|
|
Invus Global Management, LLC
13G
|
5.1% |
3/20/2026
Event 3/16/2026
|
|
| Invus Public Equities, L.P. | 4.5% | ||
| Invus Public Equities Advisors, LLC | 4.5% | ||
| Invus Global Management, LLC | 4.5% | ||
| Siren, L.L.C. | 4.5% | ||
| Avicenna Life Sci Master Fund LP | 0.6% | ||
| Avicenna Life Sci Master GP LLC | 0.6% | ||
| Ulys, L.L.C. | 0.6% | ||
| Raymond Debbane | 5.1% | ||
|
FMR LLC
13G/A
Amendment 1
|
12.5% |
3/6/2026
Event 2/27/2026
|
|
| FMR LLC | 12.5% | ||
| Abigail P. Johnson | 12.5% | ||
| Janus Henderson Group PLC 13G/A Amendment 1 | 8.4% |
2/17/2026
Event 12/31/2025
|
|
| Bain Capital Life Sciences Opportunities IV, L.P. 13G/A Amendment 3 | 10.0% |
2/17/2026
Event 12/31/2025
|
|
|
Deep Track Capital, LP
13G/A
Amendment 3
|
0% |
2/13/2026
Event 12/31/2025
|
|
| Deep Track Capital, LP | 0% | ||
| Deep Track Biotechnology Master Fund, Ltd. | 0% | ||
| David Kroin | 0% | ||
|
FMR LLC
13G
|
6.3% |
2/5/2026
Event 12/31/2025
|
|
| FMR LLC | 6.3% | ||
| Abigail P. Johnson | 6.3% | ||
| Janus Henderson Group PLC 13G | 5.2% |
11/14/2025
Event 9/30/2025
|
|
|
Deep Track Capital, LP
13G/A
Amendment 2
|
5.0% |
5/15/2025
Event 3/31/2025
|
|
| Deep Track Capital, LP | 5.0% | ||
| Deep Track Biotechnology Master Fund, Ltd. | 5.0% | ||
| David Kroin | 5.0% | ||
| Bain Capital Life Sciences Opportunities IV, L.P. 13G/A Amendment 2 | 10.0% |
5/15/2025
Event 3/31/2025
|
|
|
Point72 Asset Management, L.P.
13G/A
Amendment 1
|
2.3% |
5/15/2025
Event 3/31/2025
|
|
| Point72 Asset Management, L.P. | 2.3% | ||
| Point72 Capital Advisors, Inc. | 2.3% | ||
| Steven A. Cohen | 2.3% | ||
|
Logos Global Management LP
13D/A
Amendment 3
|
4.7% |
5/13/2025
Event 3/18/2025
|
|
| Logos Global Management LP | 4.7% | ||
| Logos Global Management GP LLC | 4.7% | ||
| Arsani William | 4.7% | ||
| Graham Walmsley | 4.7% | ||
| Logos Opportunities GP LLC | 1.0% | ||
| Logos GP LLC | 3.7% | ||
|
Paradigm Biocapital Advisors LP
13G/A
Amendment 4
|
10.0% |
2/14/2025
Event 12/31/2024
|
|
| Paradigm BioCapital Advisors LP | 10.0% | ||
| Paradigm BioCapital Advisors GP LLC | 10.0% | ||
| Senai Asefaw, M.D. | 10.0% | ||
| Paradigm BioCapital International Fund Ltd. | 9.1% | ||
| Bain Capital Life Sciences Opportunities IV, L.P. 13G/A Amendment 1 | 10.0% |
1/13/2025
Event 1/8/2025
|
| Period | Filings | Shares, Excl. Options | Value, Excl. Options |
|---|---|---|---|
| 2026 Q3 | 3 | 1.71 k | $14.7 k |
| 2026 Q2 | 202 | 103 M | $1.33 B |
| 2026 Q1 | 222 | 101 M | $1.51 B |
| 2025 Q4 | 214 | 90.7 M | $2.27 B |
| 2025 Q3 | 136 | 68.3 M | $669 M |
| 2025 Q2 | 127 | 70.6 M | $301 M |
| 2025 Q1 | 139 | 65.9 M | $248 M |
| 2024 Q4 | 164 | 71.3 M | $415 M |
| 2024 Q3 | 139 | 58.8 M | $702 M |
| 2024 Q2 | 137 | 61.5 M | $665 M |
| 2024 Q1 | 136 | 57.1 M | $647 M |
| 2023 Q4 | 129 | 52.8 M | $733 M |
| 2023 Q3 | 107 | 47.3 M | $584 M |
| 2023 Q2 | 92 | 36.4 M | $329 M |
| 2023 Q1 | 69 | 33.5 M | $117 M |
| 2022 Q4 | 72 | 33.4 M | $81.9 M |
| 2022 Q3 | 78 | 36.8 M | $101 M |
| 2022 Q2 | 81 | 34.2 M | $139 M |
| 2022 Q1 | 97 | 36.4 M | $155 M |
| 2021 Q4 | 105 | 38.7 M | $362 M |
| 2021 Q3 | 79 | 36.7 M | $1.01 B |
| 2021 Q2 | 70 | 37.4 M | $1.05 B |
| 2021 Q1 | 75 | 35.2 M | $1.16 B |
| 2020 Q4 | 59 | 35.1 M | $1.66 B |